These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20509009)

  • 21. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
    Pollio F; Pocali B; Palmieri S; Morabito P; Scalia G; Del Vecchio L; Ferrara F
    Ann Hematol; 2002 Dec; 81(12):736-8. PubMed ID: 12483372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacological management of hairy cell leukemia.
    Ramos Perez J; Ravandi-Kashani F
    Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hairy cell leukemia: treatment successes in the past 25 years.
    Golomb HM
    J Clin Oncol; 2008 Jun; 26(16):2607-9. PubMed ID: 18509168
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon in the treatment of hairy-cell leukemia.
    Ahmed S; Rai KR
    Best Pract Res Clin Haematol; 2003 Mar; 16(1):69-81. PubMed ID: 12670466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia.
    Yang MH; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):54-8. PubMed ID: 11310372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
    Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
    Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
    Else M; Dearden CE; Catovsky D
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
    Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
    Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimal treatment for untreated patients with hairy cell leukemia?
    Troussard X; Flandrin G
    J Clin Oncol; 1995 Oct; 13(10):2677-9. PubMed ID: 7595722
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
    Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I
    N Engl J Med; 2001 Jul; 345(4):241-7. PubMed ID: 11474661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
    Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
    Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hairy-cell leukaemia: first-line treatment with cladribine or pentostatin.
    Prescrire Int; 2006 Aug; 15(84):143-4. PubMed ID: 16989031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the treatment of hairy-cell leukaemia.
    Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
    Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
    Dearden CE; Else M; Catovsky D
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hairy cell leukemia: current concepts.
    Cannon T; Mobarek D; Wegge J; Tabbara IA
    Cancer Invest; 2008 Oct; 26(8):860-5. PubMed ID: 18798068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
    Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
    Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The optimal management of hairy cell leukaemia.
    Gollard R; Lee TC; Piro LD; Saven A
    Drugs; 1995 Jun; 49(6):921-31. PubMed ID: 7543840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment- or disease-related?
    Urosevic-Maiwald M; Nobbe S; Kerl K; Benz R
    J Dermatol; 2014 Apr; 41(4):329-33. PubMed ID: 24612373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.